Published in SAGE Open Med on October 08, 2013
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis (2011) 11.49
Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med (2004) 3.30
Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother (2001) 1.87
Meticillin-resistant Staphylococcus aureus in rural Asia. Lancet Infect Dis (2006) 1.80
Vancomycin: a 50-year reassessment. Clin Infect Dis (2006) 1.73
Cost-ineffectiveness of serum vancomycin levels. Eur J Clin Microbiol Infect Dis (2007) 1.40
Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PLoS One (2009) 1.32
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev (2010) 1.24
Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother (2011) 1.21
Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother (2011) 1.18
Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother (2009) 1.17
Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents (2009) 1.07
Vancomycin nephrotoxicity: myths and facts. Neth J Med (2011) 1.05
Recent changes in vancomycin use in renal failure. Kidney Int (2010) 1.03
Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy (2012) 0.94
Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother (2003) 0.93
Rapid and high-resolution distinction of community-acquired and nosocomial Staphylococcus aureus isolates with identical pulsed-field gel electrophoresis patterns and spa types. Int J Med Microbiol (2013) 0.88
Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J Chromatogr Sci (2012) 0.88
The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother (2012) 0.88
Management of antimicrobial use in the intensive care unit. Drugs (2012) 0.84
Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a prospective cohort study. Clin Microbiol Infect (2012) 0.84
Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system. Am J Health Syst Pharm (2010) 0.84
Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? Ann Intensive Care (2012) 0.82
Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int J Antimicrob Agents (2008) 0.82
Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. J Burn Care Res (2012) 0.81
Review of continuous-infusion vancomycin. Ann Pharmacother (2013) 0.80
New recommendations for vancomycin dosage for patients with MRSA pneumonia with various degrees of renal function impairment. J Infect Chemother (2005) 0.78